• Berberine Suppresses SASP in Atherosclerosis via RXRα/PPARγ/

  2026-05-09

  This study elucidates how berberine targets the RXRα/PPARγ/NEDD4 pathway to inhibit senescence-associated secretory phenotype (SASP)–driven inflammation in atherosclerotic plaques. The mechanistic insights offer a foundation for new anti-inflammatory strategies targeting cellular senescence in cardiovascular disease.

• Tacrine Hydrochloride Hydrate: Beyond Enzyme Inhibition in A

  2026-05-08

  Explore how Tacrine hydrochloride hydrate advances Alzheimer’s disease research as more than a cholinesterase inhibitor. This article delivers mechanistic clarity, practical protocol guidance, and new insight into metabolic considerations for robust neurodegenerative disease modeling.

• Zosuquidar (LY335979): Empowering MDR Cancer Research Workfl

  2026-05-08

  Zosuquidar (LY335979) 3HCl is a selective P-glycoprotein inhibitor that enables robust reversal of multidrug resistance in cancer models. This article details optimized experimental workflows, advanced applications in drug sensitization, and proven troubleshooting strategies for bench-to-clinic translation.

• Tumor-Targeted PAD4 Inhibitors: Mechanisms and In Vivo Effic

  2026-05-07

  This article reviews a recent study on meta-phenylboronic acid (m-PBA) modified PAD4 inhibitors, focusing on their tumor-selective action via the PAD4-H3cit-NETs pathway. The findings highlight the ability of these compounds to suppress tumor growth and metastasis by inhibiting histone H3 citrullination and neutrophil extracellular trap formation, with strong evidence for improved safety and tumor specificity.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-05-07

  Discover how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine empowers reproducible α2-adrenergic receptor agonist workflows, driving advances in immune rejection modulation and post-surgery osteosarcoma research. This guide delivers stepwise protocols, troubleshooting strategies, and translational insights directly informed by the latest peer-reviewed findings.

• Nicotinamide Riboside Chloride in Retinal & Metabolic Resear

  2026-05-06

  Nicotinamide Riboside Chloride (NIAGEN) is transforming workflows for modeling metabolic dysfunction and neurodegeneration by reliably boosting NAD+ and sirtuin activity. Explore how this high-purity compound streamlines stem cell differentiation, enhances oxidative metabolism, and empowers troubleshooting in complex disease models.

• Oral Dextran Microgels for Targeted Colon Cancer Nanotherapy

  2026-05-06

  This study introduces a dual-targeted oral delivery system using dextran microgels to encapsulate cisplatin/SPION lipid nanotherapeutics, achieving selective colon localization and enhanced uptake by colon cancer cells. The approach shows significant tumor inhibition and reduced metastasis in preclinical models, highlighting advances in localized epigenetic and combination cancer therapy.

• Toremifene: Potent Selective Estrogen-Receptor Modulator in

  2026-05-05

  Toremifene is a second-generation selective estrogen-receptor modulator with validated efficacy in prostate cancer research. It demonstrates robust in vitro inhibition of hormone-responsive cancer cell growth and is an established tool for dissecting estrogen receptor signaling pathways. APExBIO supplies Toremifene (A3884) at 98% purity for research use.

• Targeting Anti-Apoptotic BCL-XL and MCL-1 in Glioblastoma Th

  2026-05-05

  Koessinger et al. (2022) reveal that glioblastoma (GBM) cells exhibit elevated anti-apoptotic BCL-XL and MCL-1 expression, resulting in heightened apoptotic priming and sensitivity to BH3-mimetic inhibitors. Sequential inhibition of these proteins triggers potent anti-tumor responses, highlighting the therapeutic promise of selective BCL-XL inhibition in overcoming resistance in aggressive brain tumors.

• Rapamycin (Sirolimus): Advanced mTOR Inhibition Workflows

  2026-05-04

  Rapamycin (Sirolimus) empowers researchers to dissect mTOR signaling with nanomolar precision, enabling reliable cell proliferation suppression and pathway analysis. This guide delivers actionable protocol enhancements, troubleshooting strategies, and evidence-based tips for leveraging Rapamycin in cancer, immunology, and mitochondrial disease research.

• Amyloid Beta-Peptide (1-40): Translational Leverage in Alzhe

  2026-05-04

  Explore the mechanistic landscape and translational strategy surrounding Amyloid Beta-Peptide (1-40) (human), emphasizing new insights into calcium-mediated aggregation, membrane interactions, and best practices for maximizing experimental rigor in Alzheimer's disease research.

• GSTA1-Mediated Glutathione Depletion Drives α-Amanitin Liver

  2026-05-03

  This study reveals that GSTA1, typically a hepatic antioxidant, paradoxically intensifies α-amanitin-induced hepatotoxicity by accelerating glutathione depletion and oxidative stress. These findings reframe GSTA1 as a direct pathogenic factor and therapeutic target in acute toxin-mediated liver injury.

• PD 173074: Advanced Protocols for FGFR1 Inhibition in Adipog

  2026-05-02

  Explore how PD 173074 enables precise, nanomolar-level FGFR1 inhibition in adipogenesis and cancer research. This article delivers unique, protocol-focused insights and evidence-based guidance for optimizing pathway dissection and experimental reproducibility.

• Olive Biophenols Attenuate Aβ42 Neurotoxicity in AD Models

  2026-05-01

  This study demonstrates that olive-derived biophenols, especially oleuropein, mitigate amyloid β-peptide (1-42)-induced neurotoxicity and aggregation in both SH-SY5Y neuronal cells and an APPswe transgenic mouse model. These findings highlight the anti-amyloidogenic capacity of natural phenolics and inform future Alzheimer's disease therapeutic strategies.

• Amphotericin B: Membrane Disruption and Protoplast Insights

  2026-05-01

  Explore the unique membrane-targeting mechanism of Amphotericin B, a leading polyene antifungal antibiotic. This article goes beyond standard reviews by applying protoplast lysis insights to optimize fungal infection research protocols.

16055 records 1/1071 page Next 12345 下5页 Last page